M2 Pharma - Therapy Areas

Poxel secures new patent in Japan for Imeglimin use in type 2 diabetic patients with renal impairment

31 March 2025 - Clinical stage biopharmaceutical company Poxel SA (Euronext Paris:POXEL) announced on Monday that the Japanese Patent Office has granted a new patent (number 7635474) covering the use ...

Langhua Pharmaceutical passes US FDA's on-site inspection

31 March 2025 - Viva Biotech Holdings announced on Friday that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., successfully completed a cGMP on-site inspection by the US Food a...

Arecor signs collaboration deal with global pharma partner

26 March 2025 - Biopharmaceutical company Arecor Therapeutics plc (AIM: AREC) announced on Wednesday that it has entered into a formulation study agreement with a major global pharmaceutical company t...

ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion

14 March 2025 - Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) announced on Friday that the US Food and Drug Administration has approved an expanded label for ILUVIEN, adding an indic...

Kodiak Sciences completes enrolment in GLOW2 Phase 3 trial of tarcocimab tedromer in diabetic retinopathy

11 March 2025 - US biopharmaceutical company Kodiak Sciences Inc (Nasdaq:KOD) announced on Monday that it has completed enrolment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients...

Sterotherapeutics launches Phase 2 clinical trial of ST-002 for Cushing's Syndrome

25 February 2025 - US biopharmaceutical company Sterotherapeutics announced on Monday that it has launched a Phase 2 clinical trial of ST-002, a novel drug candidate for patients with Cushing's S...